Patients with luminal A breast cancer were often considered to have the best prognosis, followed by patients with luminal B breast cancer.3 Expression of ER is associated with favourable prognosis and can predict the efficacy of endocrine therapies including aromatase inhibitors and tamoxifen. This evidence concerns the gene CYP19A1 and breast cancer.